Tretinoin lotion - Valeant Pharmaceuticals

Drug Profile

Tretinoin lotion - Valeant Pharmaceuticals

Alternative Names: IDP 121

Latest Information Update: 11 May 2017

Price : $50

At a glance

  • Originator Valeant Pharmaceuticals International
  • Class Antiacnes; Antineoplastics; Keratolytics; Retinoids; Small molecules
  • Mechanism of Action Protein synthesis inhibitors; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Acne vulgaris

Most Recent Events

  • 12 Apr 2017 Valeant Pharmaceuticals completes a phase III trial in Acne vulgaris (In adolescents, In children, In adults) in USA (Topical) (NCT02965456)
  • 20 Mar 2017 Valeant Pharmaceuticals completes a phase III trial in Acne vulgaris (In adolescents, In children, In adults) in USA (Topical) (NCT02932306)
  • 16 Mar 2017 Valeant Pharmaceuticals announces intention to submit application to regulatory body for Acne vulgaris in 2017 (Valeant Pharmaceuticals pipeline, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top